CL2017000558A1 - Terapia de combinación - Google Patents

Terapia de combinación

Info

Publication number
CL2017000558A1
CL2017000558A1 CL2017000558A CL2017000558A CL2017000558A1 CL 2017000558 A1 CL2017000558 A1 CL 2017000558A1 CL 2017000558 A CL2017000558 A CL 2017000558A CL 2017000558 A CL2017000558 A CL 2017000558A CL 2017000558 A1 CL2017000558 A1 CL 2017000558A1
Authority
CL
Chile
Prior art keywords
combination therapy
effective amount
formula
combination
neurodegenerative
Prior art date
Application number
CL2017000558A
Other languages
English (en)
Inventor
Patrick Cornelious May
Dustin James Mergott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2017000558A1 publication Critical patent/CL2017000558A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO PARA TRATAR UNA ENFERMEDAD NEURODEGENERATIVA O COGNITIVA, QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO UNA CANTIDAD EFICAZ DE UN COMPUESTO DE LA FÓRMULA:</p> <p>O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE; EN COMBINACIÓN CON UNA CANTIDAD EFICAZ DE UN ANTICUERPO MONOCLONAL ABETA ANTI-N3PGLU.</p>
CL2017000558A 2014-09-16 2017-03-08 Terapia de combinación CL2017000558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462050967P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
CL2017000558A1 true CL2017000558A1 (es) 2017-11-10

Family

ID=54207720

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000558A CL2017000558A1 (es) 2014-09-16 2017-03-08 Terapia de combinación

Country Status (27)

Country Link
US (1) US9999624B2 (es)
EP (1) EP3193882A1 (es)
JP (1) JP6339741B2 (es)
KR (1) KR101871128B1 (es)
CN (1) CN106687136A (es)
AP (1) AP2017009794A0 (es)
AR (1) AR101740A1 (es)
AU (1) AU2015318257B2 (es)
BR (1) BR112017003571A2 (es)
CA (1) CA2956835A1 (es)
CL (1) CL2017000558A1 (es)
CO (1) CO2017001875A2 (es)
CR (1) CR20170080A (es)
DO (1) DOP2017000071A (es)
EA (1) EA031764B1 (es)
EC (1) ECSP17015977A (es)
IL (1) IL250387A0 (es)
MX (1) MX2017003414A (es)
NZ (1) NZ728636A (es)
PE (1) PE20170464A1 (es)
PH (1) PH12017500493A1 (es)
SG (1) SG11201701330PA (es)
SV (1) SV2017005389A (es)
TN (1) TN2017000072A1 (es)
TW (1) TWI599358B (es)
WO (1) WO2016043997A1 (es)
ZA (1) ZA201700826B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180119670A (ko) * 2016-03-15 2018-11-02 아스트라제네카 아베 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2018034977A1 (en) 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
US11634416B2 (en) 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
US20230236199A1 (en) * 2020-04-23 2023-07-27 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662816B2 (en) 2003-08-08 2010-02-16 Schering Corporation Cyclic amine BACE-1 inhibitors having a benzamide substituent
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
CN103068848B (zh) 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
ZA201700826B (en) 2018-12-19
SV2017005389A (es) 2018-01-17
JP6339741B2 (ja) 2018-06-06
AU2015318257B2 (en) 2018-06-14
TN2017000072A1 (en) 2018-07-04
JP2017529348A (ja) 2017-10-05
KR101871128B1 (ko) 2018-06-25
KR20170036103A (ko) 2017-03-31
CN106687136A (zh) 2017-05-17
US20170224702A1 (en) 2017-08-10
PE20170464A1 (es) 2017-04-26
EP3193882A1 (en) 2017-07-26
CA2956835A1 (en) 2016-03-24
CO2017001875A2 (es) 2017-05-19
CR20170080A (es) 2017-03-30
AP2017009794A0 (en) 2017-03-31
NZ728636A (en) 2018-05-25
US9999624B2 (en) 2018-06-19
WO2016043997A1 (en) 2016-03-24
BR112017003571A2 (pt) 2017-12-19
SG11201701330PA (en) 2017-04-27
EA031764B1 (ru) 2019-02-28
DOP2017000071A (es) 2017-06-15
PH12017500493A1 (en) 2017-08-07
IL250387A0 (en) 2017-03-30
AR101740A1 (es) 2017-01-11
TW201618786A (zh) 2016-06-01
ECSP17015977A (es) 2018-03-31
EA201790305A1 (ru) 2017-07-31
TWI599358B (zh) 2017-09-21
AU2015318257A1 (en) 2017-02-16
MX2017003414A (es) 2017-06-19

Similar Documents

Publication Publication Date Title
CL2017000558A1 (es) Terapia de combinación
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2017000335A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
IL277215A (en) Use of anti-IL-36R antibodies to treat generalized purulent urticaria
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CU24498B1 (es) Anticuerpos de factor xi
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CR20170275A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112017002433A2 (pt) anticorpos anticeramida
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
CL2018000317A1 (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
WO2016069477A3 (en) A method of treating cancer that overexpresses topbp1
CL2018001878A1 (es) Tratamiento para micro organismos que contienen quitina.